http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
간세포암종 환자에서 간동맥색전술후 혈청 Angiogenin , bFGF 및 EGF의 상승
이숭환(Soong Hwan Lee),조용현(Yong Hyeon Jo),김병훈(Byoung Hun Kim),김홍주(Hong Ju Kim),이창화(Chang Hwa Lee),이재영(Jae Young Lee),남승우(Seung Woo Nam),백인규(In Kyu Paik),박찬현(Chan Hyun Park),이동후(Dong Hoo Lee) 대한소화기학회 1996 대한소화기학회지 Vol.28 No.3
N/A Background/Aims: Angiogenesis, the induction of the formation of blood vessels, is critical to the development, progression, and metastasis of animal and human tumors. Tumor cells may produce factors which either induce or inhibit angiogenesis and that the onset of angiogenic activity is determined by the balance of these factors may be generalizable to other tumors. Hepatocellular carcinoma is hypervascular tumor and transcatheter arterial embolization(TAE) is widely used to treat patients with unresectable hepatocellular carcinoma. To evaluate changes of angiogenic factors after TAE for hepatocellular carcinoma, we investigated serum angiogenin, bFGF and EGF at the pre-TAE and the post-TAE among the seven patients with hepatocelluar carcinoma. Methods: Angiogenin, bFGF and EGF concentrations in sera were measured at pre-TAE and 3 days after TAE by employing ELISA. The statistical analysis was evaluated by Student's t-test. Results: 1) Angiogenin concentration at pre-TAE and post-TAE was 197.57+28.82ng/ml(mean+standard error) and 225.89>32.06ng/ml, respectively(p=0.022). 2) bFGF concentration at pre-TAE and post-TAE was 6.71+1.83 pg/ml and 21.68+5.58 pg/ml, respectively(p=0.036). 3) EGF concentra- tion at pre-TAE and post-TAE was 195.09+40.29 pg/rnl and 258.11+36.12 pg/ml, respectively (p=0.014). No correlation, however, was present among angiogenin, bFGF, and EGF at both of pre-TAE and post-TAE state. Conclusions: These results indicate that certain angiogenic factors, such as angiogenin, bFGF, EGF, were increased significantly at post-TAE in comparison to pre- TAE, which may reduce the therapeutic effect of TAE for hepatocellular carcinoma. We suggested that the tissue injury/destruction associated with ischemia by hepatic artery embolization are generally considered to represent a fundamental stimulus for angiogenesis in post-TAE. Therefore, suppression of angiogenesis at post-TAE may be important in improving survival for the patients with hepatocellular carcinoma since tumor growth and metastasis are angiogenesis-dependent. (Korean J Gastroenterol 1996; 28:391 - 401)
김정념,이숭환,김정식,김진호,배윤오,박성규,윤상정,한현영,이헌영 충남대학교 의과대학 의학연구소 2003 충남의대잡지 Vol.30 No.1
Omental infarction, the end result of impaired perfusion to the greater omentum, is a rare benign self-limiting clinical entity. The main clinical symptom is non-specific localized abdominal pain with a moderately raised white blood cell and erythrocyte sedimentation rate. These findings often mimic an abdominal surgical emergency. This condition is often misdiagnosed as acute appendicitis or cholecystitis. The characteristic feature of CT scan and ultrasonography provide non-invasive diagnosis in most patients with omental infarction. We report a case of patient whose CT scan showed the characteristic finding of omental infarction. The patient was improved spontaneously only with conservative care.
전신성 홍반성 루푸스에 동반된 윌슨병에 의한 전격성 간부전 1예
김태엽,이숭환,김태종,조경란,조승철,한성희,양선영,정용우,백상현,손주현,배상철,이동후,기춘석 대한간학회 2002 Clinical and Molecular Hepatology(대한간학회지) Vol.8 No.1
Patients with systemic lupus erythematosus(SLE) have a chance of developing liver involvement in their lifetime. The main cause of liver involvement in SLE patients is previous treatment with hepatotoxic drugs or hepatotropic viral hepatitis. Wilson's disease is a hereditary disorder and is usually diagnosed in patients presenting either neuropsychiatric disorders or manifestations related to chronic liver disease. Fulminant hepatic failure as the initial manifestation of Wilson's disease is rare. The relationship between systemic lupus erythematosus and Wilson's disease has not been established. We report a case of a 12-year-old girl with SLE who presented fulminant hepatic failure as an initial manifestation of Wilson's disease. The diagnosis was established with decreased serum ceruloplasmin level and the presence of Kayser-Fleischer ring. We treated with repeated plasma exchange. Despite repeated plasma exchange she died of multi-organ failure on the 16th hospital day. Considering this case, Wilson's disease should be considered as a cause of fulminant hepatic failure, especially in juvenile age cases.(Korean J Hepatol 2002;8:100-104) 전신성 홍반성 루푸스(systemic lupus erythematosus:SLE)환자는 일생동안 비정상적인 간기능 검사소견이 25-50%에서 나타나며, SLE 자체의 간침범은 드물다. 비정상 간기능 소견을 보이는 대부분의 원인은 치료약제의 간독성 혹은 바이러스 간염이 주된 간 질환의 원인이다.1,2 드물게 이러한 원인들이 배제된 경우에는 SLE와 유사한 임상양상을 보이는 자가면역성 간염과 SLE 자체의 간침범에 의한 경우를 감별해야 한다.3 그밖에 다양한 간질환이 SLE와 동반되어 나타날 수 있다. 윌슨병(Wilson's disease)은 유전적 대사질환으로 대부분 신경 정신 질환 혹은 만성 간 질환으로 나타나며 처음 증상발현이 전격성 간부전으로 나타나는 경우는 드물다.4 그러나 30세 이하에서 전격성 간부전을 보이는 경우에는 원인질환으로 윌슨병을 감별해야 한다.4 전격성 간부전으로 처음 증상 발현이 된 경우는 광범위한 간 괴사가 수일 혹은 수주 이내에 일어나므로 치명적이다. 일반적으로 윌슨병으로 인한 전격성 간부전은 간이식술 없이는 치사율이 높으므로 조기에 진단하는 것이 중요하다.The Korean Journal of Hepatology : Vol. 8. No. 1. 2002 Tae Yeob Kim, et al. SLE and Wilsonian Fulminant Hepatic Failure Figure 1. Kayser-Fleischer ring is present at the periphery of the cornea. 저자들은 SLE로 경과 관찰 중 윌슨병에 의한 전격성 간부전이 나타난 증례를 경험하였기에 문헌고찰과 함께 보고하는 바이다.
만성 B형 바이러스성 간염 환자들에 대한 lamivudine 6개월 치료 효과에 대한 전향적 연구
이동후,이숭환,남승우,감창우,김성우,노병주 대한간학회 1999 Clinical and Molecular Hepatology(대한간학회지) Vol.5 No.4
Background/Aims: The purpose of this study was to evaluate the effectiveness of lamivudine treatment in patients with chronic liver disease caused by chronic infection of hepatitis B virus (HBV). Methods: Thirty-five patients with chronic infection of HBV were included in this study who were diagnosed at Hanyang University Hospital from January 1998 to January 1999. They received 150mg of lamivudine per oral once daily for 6 months with follow-up of liver function test, serum HBV DNA and serologic markers for hepatitis B virus every two months. Lamivudine was well tolerated. Eight patients underwent liver biopsies before entering the study and follow-up biopsies were done at 5 patients. Results: Out of all 35 patients, chronic hepatitis patients histologically confirmed were 8, chronic hepatitis patients clinically diagnosed were 25 and liver cirrhosis patients clinically diagnosed were 2. The mean age was 35.7 years. Male-female ratio was 2.2:1. There was no hepatitis B surface antigen (HBsAg) negative seroconversion. The HBeAg loss rate was 26.9%(7/26) and HBeAg seroconversion rate was 10.7%(3/28) at the end of follow-up. Ten patients were anti-HBe positive prior to treatment, 3 of them became anti-HBe negative at the end of follow-up. Five patients underwent follow-up liver biopsies, in which histologic improvements were shown in 4 cases. Serum replicative HBV DNA by bDNA assay was decreased in all patients and HBV DNA was undetectable in 52.9%(9/17) at the end of treatment. Out of the 15 patients with abnormal alanine aminotransferase (ALT) levels at baseline, ALT level in 7 patients(46.7%) was normalized at treatment completion. Pretherapy ALT level was the only predictive factor for loss of HBeAg by stepwise logistic regression analysis(odds ratio : 1.0208) (95% Confidence Interval : 1.0023 ∼ 1.0396) (p value=0.0271). Conclusions: Lamivudine induced sustained suppression of HBV replication during treatment in all patients. In treating patients with lamivudine, who had chronic liver disease due to chronic ifection of HBV, the improvement of liver function test and suppression of viral replication appeared early and was sustained during the 6months treatment. This, in turn, may induce histological improvement as well. Pretherapy ALT level was the only predictive determinant for HBeAg loss during lamivudine therapy, and that should be kept in mind in selecting patients for treatment. (Korean J Hepatol 1999;5:282-290)